Tanke Biosciences Corporation
TNBI · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $9 | $0 | $0 |
| Gross Profit | -$1 | -$9 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $128 | $668 |
| SG&A Expenses | $116 | $86 | $128 | $668 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $116 | $86 | $128 | $668 |
| Operating Income | -$117 | -$94 | -$128 | -$668 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$3 | $12 | $30 | -$55 |
| Pre-Tax Income | -$120 | -$83 | -$98 | -$723 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$120 | -$83 | -$98 | -$723 |
| % Margin | – | – | – | – |
| EPS | -0.005 | -0.004 | -0.008 | -0.057 |
| % Growth | -20.5% | 50.6% | 86.1% | – |
| EPS Diluted | -0.005 | -0.004 | -0.008 | -0.057 |
| Weighted Avg Shares Out | 25,464 | 21,113 | 12,476 | 12,746 |
| Weighted Avg Shares Out Dil | 25,464 | 21,113 | 12,476 | 12,746 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $56 | $56 | $2 |
| Depreciation & Amortization | $1 | $9 | $128 | $668 |
| EBITDA | -$116 | -$18 | $30 | -$55 |
| % Margin | – | – | – | – |